We're hiring ! Specifically....we are seeking to appoint a creative and motivated Postdoctoral Training Fellow to study how drug resistance emerges in homologous recombination defective (HRD) breast cancers and how this could be targeted. jobs.icr.ac.uk/vacancies/13...

RFK Jr. taps his top deputy, Jim O’Neill, to be the new CDC director. Both men appear to wear skinny ties from Otaa. Otaa's ties are made in China from microfiber, a kind of plastic that, under the right conditions, can migrate to your balls.

Thrilled to share our latest work, just published in @nature.com ⬇ www.nature.com/articles/s41... We discovered that PARP inhibitors 💊 trigger histone eviction from the chromatin and this creates a hidden vulnerability in PARPi resistant tumors. 🧵 (1/8)

our bit funded by @breastcancernow.bsky.social @cancerresearchuk.org and carried out @icr.ac.uk

With super Roman Chabanon and Sophie Postal Vinay, we show that inhibition of RNA editor ADAR1 causes a new form of BRCA synthetic lethality>autocrine inferferon poisoning. Relevant for ADAR1 drug discovery. Could provide a mechanistically different approach than PARPi. rdcu.be/eyo6t

Academic writing is a craft. ✍️ You’re not born knowing how to write great papers, succinct emails, or convincing proposals. You get better by doing it badly, then better, then well. Your writing is the first thing people see before they meet you. Make it count.

This is fascinating:

Incredibly humbled and honoured to have been awarded the 2025 Research Prize from @thelisterinstitute.bsky.social. ❤️ 🧬 We’re harnessing high-resolution molecular profiling + AI to uncover how cancer disables the immune system and find ways of restoring it. @icr.ac.uk #bcsm #ai #CancerResearch

🧬 Excited to announce the 2nd Euro Cancer DepMap Symposium bringing together leading minds in functional genomics, cancer vulnerabilities, AI, CRISPR and anti-cancer target discovery.📍Join us in Milan for cutting-edge science, open discussion & collaboration. #EuroDepMap #CancerResearch #CRISPR

Following the success of the first European Cancer Dependency Map Symposium in 2023, we are excited to announce the 2nd edition, to be held at Human Technopole on the 20th November 2025. Registration and Poster submission now open! humantechnopole.it/en/trainings... youtu.be/x2erCuovGvc #EuroDepMap

Loving “pertomics”. Going to push the term “buffomics” too.

We're looking for a Scientific Operations Project Manager to join us at ICR, London. Role is aimed at establishing new funding streams, collaborations with biotech. and pharma and managing collaborations with other academic groups. jobs.icr.ac.uk/vacancies/11...

The OptiTROP-Breast01 phase 3 trial evaluated sacituzumab tirumotecan (sac-TMT) versus chemotherapy in patients with heavily pretreated, locally recurrent or metastatic triple-negative #BreastCancer www.nature.com/articles/s41... ✅Sac-TMT significantly improved progression-free survival PFS

showing true (!) synthetic lethality www.nature.com/articles/nat... www.nature.com/articles/nat...

this week 20 years ago, Nature published two seminal papers showing for the first time that BRCA-mutant cells were selectively sensitive to PARP inhibitors, paving the way for clinical trials and approval of PARP inhibitors for patients with BRCA-mutant ovarian and breast cancers, and beyond.

Interested in starting your cancer research career in London ?We're looking for a Scientific Officer to support our work on synthetic lethality in triple negative and BRCA1/2 mutant cancers. Ideal job for a new graduate who wants to kick start their research career. jobs.icr.ac.uk/vacancies/12...

And Elvis 75 the best single never released

PAPER OUT!! 🥳🎉💃🏻🕺🏻💃🏻🕺🏻 A redefined InDel taxonomy provides insights into mutational signatures @NatureGenet Brainchild of the amazing #GeneKoh (Sir Jeffrey Cheah ECR) Tweetorial below!! 👇 1/n www.nature.com/articles/s41...

www.bbc.co.uk/news/article.... Excellent news for breast cancer patients, based on great work from ICR scientists including our own Nick Turner.

A must for all DNA repair aficionados! Egmond DNA Repair Meeting → April 19–24, 2026 🇳🇱 ✔️ Confirmed top speakers ✔️ Ample opportunities for talks & posters Don’t miss it: dnarepairmeeting-egmond2026.com

We had the most fantastic joint lab retreat with our friends @josjonkers.bsky.social and Sabine Linn and their super smart colleagues @nkinl.bsky.social. The start of a lot of collaborative work targeting HRD and ILC.

Super nice review on metastasis organo-tropism⬇️ the process where tumor cells preferentially spread to specific distant organs, and represents a critical aspect of cancer biology with profound implications for patient outcomes. #CDH1 www.cell.com/trends/cance...

Surprising findings of BRCA mutations on the Fallopian tubes. Result of a tremendous team effort with @shenhui1986.bsky.social @vainstitute.bsky.social, Chuck Drescher @fredhutch.bsky.social, and Jarrod Marto @danafarber.bsky.social. @pennmedcso.bsky.social www.nature.com/articles/s41...

With Syed Haider we show that like BRCAness, phenocopies of Rb genomic defects (RBness) are common and in cancer and predict genetic dependencies. Work from @icr.ac.uk funded by @breastcancernow.bsky.social @cancerresearchuk.org www.science.org/doi/10.1126/...

📢The programme for #DDRCT25 is now available! Visit our website to explore the exciting sessions, speakers, and key topics we have in store. ➡️Check it out here: fusion-conferences.com/conference/177

Ben O'Leary & I are looking for a #postdoc to join us in @cec-icr.bsky.social to work on collaborative @cancerresearchuk.org RadNet project about the interrelationship between genome & epigenome instability and radiotherapy response. Details & apply here: jobs.icr.ac.uk/vacancies/11... @icr.ac.uk

For those of you interested in cancer synthetic lethality, this should be a v interesting Gordon Conference organised by @mgarnett.bsky.social @vazquezf.bsky.social & Benjamin Schwartz- highly recommended ! www.grc.org/synthetic-le...

🚨We’re recruiting!🚨 Looking directly at my oncology drug discovery biology folks 👀 3️⃣ faculty-level biology posts, including leadership in drug discovery & target validation. Drug discovery experience a must, industry experience valued, you’ve gotta be in London. ICR.ac.uk/CCDDjobs for info/contact

Happy to post a new study on BioRxiv, where we show Integrated Stress Response activation as an off-target effect of multiple clinically evaluated WEE1 inhibitors. Team effort with the lab of Dan Durocher @durocher1.bsky.social and many others. www.biorxiv.org/content/10.1...

🎉 We are delighted that Professor Paul Workman has been elected as a Fellow of The American Association for Cancer Research Academy @theaacr.bsky.social Professor Workman is honoured for his impact on cancer research and is among the 33 new AACR Fellows in 2025. www.icr.ac.uk/about-us/icr...

If you like chromatin remodellers and centromeres, this might be of interest. In it, we generated omics data from isogenic PBRM1 cell lines, which we hope is of use to the community, freely available (when evil forces aren't messing with the publicly funded websites 🙄) www.nature.com/articles/s41...

I can’t believe this needs to be said. TransGENIC mice are not TransGENDER mice

If Trump was President in 1940

BRCA1 turned 30 🎉 To celebrate, Jos Jonkers and I explored three decades of BRCA1 research - what we’ve learned about its biology, its role in tumorigenesis and future directions to improve the life of BRCA1 mutation carriers. Now out in Cancer Discovery ⬇️: aacrjournals.org/cancerdiscov...

Work led by Syed Haider and our team at the @breastcancernow.bsky Toby Robins Research Centre @icr.ac.uk and funded by @cancerresearchuk.org

We show transcriptomic buffering of tumour suppressor loss via syn. lethal genes is not anecdotal but a cancer hallmark. Buffering also seen in BRCAness, predicts penetrant syn leth effects and outcome. @icr.ac.uk @cancerresearchuk.org @breastcancernow.bsky.social www.nature.com/articles/s41...

Yesterday Keir Starmer thanked Donald Trump for "changing the conversation" on Ukraine. Today's conversation:

I will never forget the photo of Zelenskyy’s face after he saw Russia’s war crimes in Bucha in 2022. He seemed to age years in an afternoon. Watching him constantly cross the world asking for aid that should have been thrown at him is one of the deepest shames of our age.

We have overhauled www.elbcc.org and ask all existing and future participants to register and indicate their preferred working groups. Check the site, current members, and spread the word! @christinedesmedt.bsky.social @pwbderksen.bsky.social @lobularbcuk.bsky.social @lobularbca.bsky.social

Online Now: Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumors Online now:

The difference between having data and having beliefs.

I'm super excited to share our study in collaboration with @jnpruneda.bsky.social, published today in @embojournal.org! We show that PARPs are modified with a non-canonical ester-linked mono-ADP-ribosylated ubiquitin species for the first time in cells: www.embopress.org/doi/full/10....

Happy to share our review on the cellular responses to RNA damage 🥂 Congrats to joined first authors Jacqueline Cordes & @shubozhao.bsky.social www.cell.com/cell/fulltex...

I wrote last week urging Pharma CEOs to speak up about the Trump administration. Unfortunately, some of them have.

The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. Read our statement: https://buff.ly/4gRXNB8

🚨 New paper alert! 🚨 Excited to share our latest work in Nature Communications spearheaded by brilliant @omaiques.bsky.social and thanks to all our collaborators—we show how matrix mechano-sensing at the invasive front induces a cytoskeletal and transcriptional memory that supports metastasis! 🧵⬇️

We show that oncogenic LoF missense mutations in PPP2R1A cause in vitro and in vivo ATRi sensitivity in ovarian clear cell carcinoma, even when combined with ARID1A mutation. Good team effort led by James Stewart, funded by CRUK, carried out at @icr.ac.uk rdcu.be/d9BMa